module 2 management of asthma

Question 1

Mild intermittent characteristics

Answer 1

s/s  2 times per week
nocturnal awakenings  2 times/month
exacerbations brief
lung function nml between exacerbation
limited peak flow variability

Question 2

mild intermittent short term relief

Answer 2

short acting B agonist as needed for s/s or prior to expected exposure

Question 3

Mild intermittent long term control

Answer 3

no meds necessary

Question 4

mild persistant characteristics

Answer 4

s/s > 2 times/week
nocturnal awakenings > 2 times/month
exacerbations brief and may affect activity 
lung function nml when asymptomatic 
peak flow dec. 20-30% when symptomatic

Question 5

mild persistant short term relief

Answer 5

short acting B agonist as needed

Question 6

mild persistant long term control

Answer 6

inhaled low dose corticosteroid

alternative: leukotriene pathway modifier, mast cell stabilizer, or theophyilline

Question 7

moderate persistent characteristics

Answer 7

• daily s/s
• nocturnal awakenings > 1 time/week
• freq exacerbations lasting days and affecting activity
• lung function 60-80% of predicted
• peak flow variability > 30%

Question 8

moderate persistent short term relief

Answer 8

short acting B agonist as needed

Question 9

moderate persistent long term control

Answer 9

preferred: low to med. dose inhaled steroid and LABA
alternative:
- med-dose inhaled steroid along
- low to med-dose inhaled steroid plus sustained release theophylline
- low to med-dose inhaled steroid plus leukotriene pathway modifier

Question 10

severe persistent characteristics

Answer 10

continual s/s
limited activity
freq. nocturnal awakenings
freq. severe exacerbations
lung function <60% of predicted 
peak flow variability >30%

Question 11

severe persistent short term relief

Answer 11

short acting B agonist for s/s

Question 12

Severe persistent long term control

Answer 12

preferred: high-dose inhaled corticosteroid and LABA
alternative:
- oral corticosteroids if needed